ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

New Study Highlights the Role of Artificial Intelligence in Diagnosing Oral Squamous Cell Carcinoma, Offering Hope for Early Detection

New Study Highlights the Role of Artificial Intelligence in Diagnosing Oral Squamous Cell Carcinoma, Offering Hope for Early Detection

Kansas City, KS - A new study published today explores the revolutionary potential of artificial intelligence (AI) in diagnosing oral squamous cell carcinoma (OSCC), a common but often late-diagnosed cancer that affects the oral cavity. The study, titled “Role of Artificial Intelligence in the Diagnosis of Oral Squamous Cell Carcinoma: A Systematic Review,” was conducted by Tanay Chowdhury, Pratik Kasralikar, Abdul Aleem Syed, Ramakrishna Tumati, Sandipkumar Patel, and Dheeraj Kommineni. These researchers are paving the way forward for advanced research alongside leading researchers in the fields of oncology and artificial intelligence, including Dr. Farouk Mutai and Dr. Sarah Ndirangu. These researchers are renowned for their groundbreaking work in using AI to improve cancer diagnosis, particularly in resource-limited settings.

Oral squamous cell carcinoma is responsible for more than 10,000 cancer-related deaths each year in the United States, with over 50,000 new cases diagnosed annually. Early detection of OSCC is crucial for successful treatment and improving survival rates. However, this type of cancer is often diagnosed at later stages, where treatment options are limited, and the prognosis is poor. The systematic review reveals that AI, specifically machine learning algorithms, can aid in the early diagnosis of OSCC by analyzing medical images, biopsies, and patient data more efficiently than traditional methods, potentially saving the lives of thousands of Americans each year.

"The ability of AI to assist in diagnosing oral cancers at earlier stages could significantly improve survival outcomes," said Mr. Lukas Meier, Senior Journalist at Alpine Vision Media. “This research not only highlights the potential of AI but also emphasizes the importance of integrating these technologies into clinical practice, especially in resource-limited settings where access to specialized care may be scarce.” Dr. Farouk Mutai, a leading oncologist from Uganda, and Dr. Sarah Ndirangu, an AI researcher and oncologist based in Kenya, have been instrumental in the development of AI-driven diagnostic tools for cancer detection. Their work has paved the way for AI to be integrated into cancer care in regions with limited access to healthcare specialists. Their research focuses on addressing diagnostic challenges in underserved regions and demonstrates the transformative potential of AI in improving patient outcomes.

In the United States, the economic impact of early detection could be significant. The integration of AI into OSCC diagnosis could help reduce the overall treatment expenses for OSCC patients by detecting cancers earlier, when treatment is more affordable and effective. The U.S. currently spends over $4 billion annually on the treatment of late-stage OSCC cases, and early detection powered by AI could potentially lower these costs significantly, while also improving survival rates. The systematic review suggests that AI-powered diagnostic tools could play a critical role in overcoming current limitations in diagnosing OSCC, particularly in developing regions. It calls for further research and investment in AI technologies to enhance diagnostic capabilities worldwide.

Citation: Chowdhury T, Kasralikar P, Aleem Syed A, et al. (April 06, 2025) Role of Artificial Intelligence in the Diagnosis of Oral Squamous Cell Carcinoma: A Systematic Review. Cureus 17(4): e81800. DOI 10.7759/cureus.81800

Media Contact
Company Name: Alpine Vision Media
Contact Person: Lukas Meier
Email: Send Email
Country: Switzerland
Website: https://alpinevisionmedia.com/

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.